---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-016260"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-05-12T13:30:19+00:00"
generated_at: "2026-05-12T13:31:21.712384+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports Annamycin shows no clinically significant cardiotoxicity in 90-patient pooled analysis

## Summary
- Pooled analysis of 90 R/R AML patients across 5 trials; 78 had source-verified pre/post ejection fraction assessments.
- No patients met criteria for clinically significant left ventricular dysfunction; mean ejection fraction stable.
- Cardiac safety review conducted by Cleveland Clinic cardio-oncology laboratory.
- Data presented at EHA 2026 Congress; Annamycin dosed beyond conventional anthracycline lifetime limits.
- Management believes results support broader positioning in AML and other oncology indications.

## SEC filing metadata
- accession: 0001437749-26-016260
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-05-12T13:30:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926016260/0001437749-26-016260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926016260/mbrx20260511d_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-016260
- JSON: https://secwatch.observer/filing/0001437749-26-016260.json
- Plain text: https://secwatch.observer/filing/0001437749-26-016260.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.